RU2019140933A - Средства, пути применения и способы лечения - Google Patents
Средства, пути применения и способы лечения Download PDFInfo
- Publication number
- RU2019140933A RU2019140933A RU2019140933A RU2019140933A RU2019140933A RU 2019140933 A RU2019140933 A RU 2019140933A RU 2019140933 A RU2019140933 A RU 2019140933A RU 2019140933 A RU2019140933 A RU 2019140933A RU 2019140933 A RU2019140933 A RU 2019140933A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- variable domain
- antigen
- binding fragment
- chain containing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 239000012634 fragment Substances 0.000 claims 173
- 230000027455 binding Effects 0.000 claims 170
- 239000000427 antigen Substances 0.000 claims 167
- 102000036639 antigens Human genes 0.000 claims 167
- 108091007433 antigens Proteins 0.000 claims 167
- 102100037632 Progranulin Human genes 0.000 claims 19
- 101710114165 Progranulin Proteins 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 16
- 102100032889 Sortilin Human genes 0.000 claims 14
- 108010014657 sortilin Proteins 0.000 claims 14
- 230000003247 decreasing effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 210000004556 brain Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 101000868139 Homo sapiens Sortilin Proteins 0.000 claims 3
- 241000699670 Mus sp. Species 0.000 claims 3
- 230000012202 endocytosis Effects 0.000 claims 3
- 230000029142 excretion Effects 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000000692 cap cell Anatomy 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700419 | 2017-07-20 | ||
| DKPA201700419 | 2017-07-20 | ||
| PCT/EP2018/069460 WO2019016247A2 (en) | 2017-07-20 | 2018-07-18 | AGENTS, USES AND METHODS OF TREATMENT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019140933A true RU2019140933A (ru) | 2021-08-20 |
| RU2019140933A3 RU2019140933A3 (enExample) | 2021-10-28 |
Family
ID=63113476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019140933A RU2019140933A (ru) | 2017-07-20 | 2018-07-18 | Средства, пути применения и способы лечения |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10894833B2 (enExample) |
| EP (1) | EP3655438A2 (enExample) |
| JP (2) | JP7563975B2 (enExample) |
| KR (1) | KR102800556B1 (enExample) |
| CN (3) | CN119161480A (enExample) |
| AR (1) | AR112563A1 (enExample) |
| AU (1) | AU2018303175B2 (enExample) |
| BR (1) | BR112019005428A2 (enExample) |
| CA (1) | CA3069391A1 (enExample) |
| CL (1) | CL2020000070A1 (enExample) |
| CO (1) | CO2019014090A2 (enExample) |
| CR (1) | CR20200027A (enExample) |
| DO (1) | DOP2020000006A (enExample) |
| EA (1) | EA201992688A1 (enExample) |
| EC (1) | ECSP20002935A (enExample) |
| IL (1) | IL271728B2 (enExample) |
| JO (1) | JOP20200007A1 (enExample) |
| MA (1) | MA49633A (enExample) |
| NI (1) | NI202000005A (enExample) |
| PE (1) | PE20210467A1 (enExample) |
| PH (1) | PH12019502869A1 (enExample) |
| RU (1) | RU2019140933A (enExample) |
| SG (1) | SG11201912228WA (enExample) |
| TW (1) | TW201908342A (enExample) |
| WO (1) | WO2019016247A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211980T1 (hr) | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| MY202133A (en) | 2018-07-13 | 2024-04-05 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| CN113645996B (zh) * | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
| WO2020252066A1 (en) * | 2019-06-11 | 2020-12-17 | Alector Llc | Anti-sortilin antibodies for use in therapy |
| US20230235048A1 (en) * | 2020-06-24 | 2023-07-27 | Andriani IOANNOU | Antibodies recognizing sortilin |
| CA3252861A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce the degradation of extracellular targets in lysosomes |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0486622B1 (en) | 1989-08-09 | 1998-11-04 | Rhomed, Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| DE69424687T2 (de) | 1993-03-09 | 2000-09-07 | Genzyme Corp., Cambridge | Verfahren zur isolierung von proteinen aus milch |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | ＨＥＲ２／ｎｅｕに対するヒトモノクローナル抗体 |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| ES2380055T3 (es) | 2002-12-20 | 2012-05-08 | H. Lundbeck A/S | Modulación de la actividad de neurotrofinas; método de escrutinio |
| BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| EP2120997B1 (en) | 2006-12-21 | 2017-03-01 | H. Lundbeck A/S | Modulation of activity of proneurotrophins |
| WO2009097006A2 (en) | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
| EP3009143B1 (en) * | 2008-01-16 | 2018-10-03 | Neurodyn Life Sciences Inc. | Progranulin for use in treating parkinson's disease or alzheimer's disease |
| KR101614558B1 (ko) | 2008-04-27 | 2016-04-22 | 하. 룬드벡 아크티에셀스카브 | 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도 |
| WO2009154995A2 (en) * | 2008-05-27 | 2009-12-23 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor (il-10r) antibodies and methods of use |
| WO2010022175A1 (en) | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| WO2010069331A2 (en) | 2008-12-19 | 2010-06-24 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| US9822366B2 (en) | 2012-11-02 | 2017-11-21 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
| WO2015143300A1 (en) * | 2014-03-21 | 2015-09-24 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
| IL247942B (en) * | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| HRP20211980T1 (hr) * | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| CN114984209B (zh) * | 2017-04-05 | 2025-08-29 | 正大天晴药业集团股份有限公司 | 靶向pd-1、tim-3及lag-3的组合疗法 |
| MY202133A (en) * | 2018-07-13 | 2024-04-05 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| CN113151432A (zh) * | 2020-04-14 | 2021-07-23 | 郁金泰 | 神经退行性疾病检测和治疗的新靶标 |
-
2018
- 2018-07-17 US US16/037,790 patent/US10894833B2/en active Active
- 2018-07-18 CR CR20200027A patent/CR20200027A/es unknown
- 2018-07-18 CA CA3069391A patent/CA3069391A1/en active Pending
- 2018-07-18 CN CN202411383695.6A patent/CN119161480A/zh active Pending
- 2018-07-18 CN CN202411383796.3A patent/CN119161481A/zh active Pending
- 2018-07-18 JP JP2020502415A patent/JP7563975B2/ja active Active
- 2018-07-18 KR KR1020207001250A patent/KR102800556B1/ko active Active
- 2018-07-18 SG SG11201912228WA patent/SG11201912228WA/en unknown
- 2018-07-18 EA EA201992688A patent/EA201992688A1/ru unknown
- 2018-07-18 WO PCT/EP2018/069460 patent/WO2019016247A2/en not_active Ceased
- 2018-07-18 IL IL271728A patent/IL271728B2/en unknown
- 2018-07-18 RU RU2019140933A patent/RU2019140933A/ru unknown
- 2018-07-18 AU AU2018303175A patent/AU2018303175B2/en active Active
- 2018-07-18 PE PE2020000100A patent/PE20210467A1/es unknown
- 2018-07-18 EP EP18750343.8A patent/EP3655438A2/en active Pending
- 2018-07-18 MA MA049633A patent/MA49633A/fr unknown
- 2018-07-18 JO JOP/2020/0007A patent/JOP20200007A1/ar unknown
- 2018-07-18 CN CN201880047918.8A patent/CN110945029B/zh active Active
- 2018-07-18 BR BR112019005428A patent/BR112019005428A2/pt not_active IP Right Cessation
- 2018-07-19 TW TW107124976A patent/TW201908342A/zh unknown
- 2018-07-20 AR ARP180102043 patent/AR112563A1/es not_active Application Discontinuation
-
2019
- 2019-12-13 CO CONC2019/0014090A patent/CO2019014090A2/es unknown
- 2019-12-18 PH PH12019502869A patent/PH12019502869A1/en unknown
-
2020
- 2020-01-09 CL CL2020000070A patent/CL2020000070A1/es unknown
- 2020-01-09 DO DO2020000006A patent/DOP2020000006A/es unknown
- 2020-01-16 EC ECSENADI20202935A patent/ECSP20002935A/es unknown
- 2020-01-17 NI NI202000005A patent/NI202000005A/es unknown
- 2020-12-11 US US17/118,934 patent/US20210292414A1/en active Pending
-
2024
- 2024-05-28 JP JP2024085982A patent/JP2024119866A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| US20230399388A1 (en) | Methods for treating inflammation using antibodies to kallidin and des-arg10-kallidin | |
| JP2020527152A5 (enExample) | ||
| TWI640537B (zh) | ＰＤＧＦ受體β結合多肽 | |
| JP2024150751A5 (enExample) | ||
| JP2020002172A5 (enExample) | ||
| JP2018529635A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2016533335A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2009532336A5 (enExample) | ||
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2014519334A5 (enExample) | ||
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| TW201406391A (zh) | 抗－ｉｌ－２３抗體 | |
| HRP20171580T1 (hr) | Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba | |
| US12479920B2 (en) | PD1 and VEGFR2 dual-binding agents | |
| JP2020522280A5 (enExample) | ||
| JP2015509960A5 (enExample) | ||
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| JP2013508292A5 (enExample) | ||
| US20240383980A1 (en) | CD3/CD25 Antibodies For Neuro-Immune Diseases |